Your browser doesn't support javascript.
loading
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Barretina-Ginesta, Maria-Pilar; Monk, Bradley J; Han, Sileny; Pothuri, Bhavana; Auranen, Annika; Chase, Dana M; Lorusso, Domenica; Anderson, Charles; Abadie-Lacourtoisie, Sophie; Cloven, Noelle; Braicu, Elena I; Amit, Amnon; Redondo, Andrés; Shah, Ruchit; Kebede, Nehemiah; Hawkes, Carol; Gupta, Divya; Woodward, Tatia; O'Malley, David M; González-Martín, Antonio.
Afiliação
  • Barretina-Ginesta MP; GEICO and Medical Oncology Department, Institut Català d'Oncologia, Sant Ponç, Avinguda de França, Girona 17007, SpainGirona Biomedical Research Institute, Girona University, Girona, Spain.
  • Monk BJ; GOG Foundation and Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA.
  • Han S; BGOG and Department of Gynaecology and Obstetrics,University Hospitals Leuven, Leuven, Belgium.
  • Pothuri B; GOG Foundation and Department of Obstetrics/Gynecology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
  • Auranen A; NSGO and Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.
  • Chase DM; GOG Foundation and Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA.
  • Lorusso D; MITO and Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Anderson C; GOG and Willamette Valley Cancer Institute, Eugene, OR, USA.
  • Abadie-Lacourtoisie S; GINECO and Oncologie Médicale Gynécologique, Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France.
  • Cloven N; GOG and Division of Gynecologic Oncology, Texas Oncology (US Oncology Network), Fort Worth, TX, USA.
  • Braicu EI; AGO and Department for Gynaecology, Campus Virchow Clinic, Charité - Universitätsmedizin Berlin, Berlin, GermanyDepartment of Obstetrics and Gynecology, Stanford University, Palo Alto, CA, USA.
  • Amit A; ISGO and Division of Obstetrics and Gynecology, Rambam Medical Centre, Haifa, Israel.
  • Redondo A; GEICO and Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
  • Shah R; Open Health Evidence and Access, Bethesda, MD, USAHealth Economics and Outcomes Research, Daiichi Sankyo, Basking Ridge, NJ, USA.
  • Kebede N; Open Health Evidence and Access, Bethesda, MD, USAReal World Evidence Science, Oncology Business Unit, AstraZeneca, Gaithersburg, MD, USA.
  • Hawkes C; GSK, Brentford, UK.
  • Gupta D; GSK, Waltham, MA, USA.
  • Woodward T; GSK, Philadelphia, PA, USAGlobal Value and Evidence Strategy, Pfizer, Baltimore, MD, USA.
  • O'Malley DM; GOG and Division of Gynecologic Oncology, Ohio State University COM - James CCC, Columbus, OH, USA.
  • González-Martín A; GEICO and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, SpainCIMA-University of Navarra, Program in Solid Tumors, Pamplona, Spain.
Ther Adv Med Oncol ; 14: 17588359221126149, 2022.
Article em En | MEDLINE | ID: mdl-36172173
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies Idioma: En Revista: Ther Adv Med Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies Idioma: En Revista: Ther Adv Med Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha